| Market Cap | 79.85K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -1.62M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -94.00% |
| Sales | 34M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -95.00% |
| Dividend | N/A | Price/Book | 0.01 | EPS next 5Y | - | 52W High Chg | -99.00% |
| Recommedations | - | Quick Ratio | 0.49 | Shares Outstanding | 199.63M | 52W Low Chg | - |
| Insider Own | 0.87% | ROA | -3.64% | Shares Float | 197.90M | Beta | -0.50 |
| Inst Own | - | ROE | -58.95% | Shares Shorted/Prior | -/- | Price | 0.00040 |
| Gross Margin | 13.90% | Profit Margin | -4.77% | Avg. Volume | 15,199 | Target Price | - |
| Oper. Margin | -1.85% | Earnings Date | - | Volume | 2,500 | Change | 0.00% |
Sunwin Stevia International, Inc. produces and sells natural sweeteners and other pharmaceutical products primarily in the People's Republic of China. It operates through two segments, Stevioside; and Corporate and Other Pharmaceutical. The company produces and sells various steviol glycosides with rebaudioside A and stevioside as the principal components. It offers Steviosin, a low calorie stevia extract for medicinal use; and OnlySweet, a zero calorie, tabletop sweetener to food and drug manufacturers, and ingredient distributor foreign trade companies. The company also produces and sells Metformin, a medication for the treatment of type 2 diabetes. Sunwin Stevia International, Inc. is based in Qufu, China.
